MARKET

KALA

KALA

Kala Pharmaceuticals Inc
NASDAQ
0.5753
-0.0059
-1.02%
Opening 14:32 12/30 EST
OPEN
0.6090
PREV CLOSE
0.5812
HIGH
0.6090
LOW
0.5575
VOLUME
913.31K
TURNOVER
--
52 WEEK HIGH
20.60
52 WEEK LOW
0.5100
MARKET CAP
4.72M
P/E (TTM)
-0.0969
1D
5D
1M
3M
1Y
5Y
1D
KALA BIO Directors Plan Conditional Resignations Tied to Vote
TipRanks · 1d ago
Weekly Report: what happened at KALA last week (1222-1226)?
Weekly Report · 1d ago
Why Did Indaptus Therapeutics Surge 64% In After-Hours Trading?
Benzinga · 6d ago
Weekly Report: what happened at KALA last week (1215-1219)?
Weekly Report · 12/22 10:07
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 12/19 21:05
KALA BIO Announces New CEO and Funding Deal
TipRanks · 12/16 14:59
Tracking Baker Brothers Portfolio - Q3 2025 Update
Seeking Alpha · 12/16 14:19
Weekly Report: what happened at KALA last week (1208-1212)?
Weekly Report · 12/15 10:13
More
About KALA
KALA BIO, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the research, development, and commercialization of therapies for rare and severe diseases of the eye. The Company’s biologics-based investigational therapies utilize its proprietary mesenchymal stem cell secretome (MSC-S) platform. The Company’s product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biocfactors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially correct the impaired corneal healing, which is an underlying etiology of multiple severe ocular diseases; KPI-014 specific for inherited retinal degenerative diseases. KPI-012 is in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing. The Company is also engaged in the development of KPI-012 for the treatment of Limbal Stem Cell Deficiency and other rare corneal diseases.

Webull offers KALA BIO Inc stock information, including NASDAQ: KALA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KALA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KALA stock methods without spending real money on the virtual paper trading platform.